Benefits
Cognition after stroke: small Russian studies only
In an open study of stroke patients with mild cognitive impairment, 20 mg a day for two months improved a cognitive screening score and verbal fluency more than in a comparison group, with no blinding and no placebo described. A study against piracetam in vascular and post-traumatic cognitive disorders is often cited, but it has no indexed abstract, so its size, design and results cannot be checked.
Memory and focus in healthy people: no controlled trial
PubMed indexes no controlled trial of Noopept for memory, focus or learning in healthy adults. Its reputation as a tiny dose that sharpens thinking comes from animal work, user anecdotes and Russian labeling written for patients. The few Russian studies in healthy people looked at adapting to heat, cold and thin air in young volunteers, or at work capacity when older teachers added self-massage to Noopept; neither was a memory trial.
Brain cell protection in lab and animal models
In cultured human cortical neurons, Noopept limited cell death and free radical damage caused by hydrogen peroxide, and in rats it raised hippocampal messenger RNA for the growth factors NGF and BDNF. Every mechanism paper cited on this page includes scientists from the institute that created the drug, and none of it shows protection of the human brain.
Regulatory status: an unapproved drug, not a supplement
FDA warning letters have told US sellers that Noopept products are unapproved new drugs rather than dietary supplements, and US law does not let unapproved drugs enter supplements as new ingredients. European medicines laboratories report it is not authorised for human use in the EU or Australia. In Russia it is a registered medicine sold as 10 mg tablets.
What is actually in the bottle is unpredictable
When US researchers tested ten cognitive supplements, every one contained omberacetam, at about 5 to 41 mg per serving against a usual medical dose of 10 mg. Nine of twelve declared drug amounts were wrong, and two products held undeclared unapproved drugs such as phenibut or picamilon. Medicines control labs in Europe and Australia have also intercepted bulk Noopept raw material of up to 100% purity.
Mechanism of action
Prodrug of the brain peptide cyclo-prolylglycine
In rats, Noopept itself was undetectable in brain an hour after injection, while cyclo-prolylglycine, a small cyclic peptide the brain makes on its own, rose about 2.5-fold. Plasma and brain enzymes formed it from Noopept in vitro, so the developers describe the drug as a prodrug of that peptide.
Growth factor gene expression in the hippocampus
Single and 28-day dosing in rats raised hippocampal messenger RNA for NGF and BDNF, and the effect did not fade with repeated dosing. In the cortex a single dose lowered expression and chronic dosing raised BDNF only slightly. These are gene expression changes in rats, not memory gains in people.
Alpha7 nicotinic receptor signaling
In rat hippocampal slices, Noopept increased the firing of inhibitory interneurons, and drugs that block alpha7 nicotinic acetylcholine receptors almost abolished the effect. That ties it to cholinergic signaling involved in attention and memory, but only at the level of brain slice recordings.
Antioxidant protection in cultured neurons
In human cortical neurons exposed to hydrogen peroxide, Noopept improved survival in a dose-dependent way and reduced free radical build-up and lipid peroxidation, outperforming piracetam and vitamin E in the same experiments. Concentrations in a culture dish do not show what an oral dose achieves in the brain.
Clinical trials
Open prospective Russian study of Noopept in stroke patients with mild cognitive impairment, compared with a control group (Amelin AV, Iliukhina AIu, Shmonin AA 2011, Zh Nevrol Psikhiatr Im S S Korsakova 111(10 Pt 1):44-6, PMID 22500312).
60 stroke patients; the abstract says they were treated with Noopept during 12 months, yet the abstract reports a Noopept dose of 20 mg a day for 2 months and does not say how patients were split between groups.
MMSE scores and verbal association tasks improved significantly after 2 months in the Noopept group compared with controls, and the global efficacy rating showed mild improvement versus no change in controls. The authors described safety as high but the abstract gives no adverse event counts. The design was open, with no blinding and no placebo described, and only a short Russian-language abstract is indexed.
Comparative clinical study of Noopept and piracetam from the clinical psychopharmacology laboratory of the Zakusov Institute of Pharmacology in Moscow, the institute whose scientists designed Noopept (Neznamov GG, Teleshova ES 2009, Neurosci Behav Physiol 39(3):311-21, PMID 19234797).
Patients with mild cognitive disorders caused by cerebrovascular disease or brain injury.
This head-to-head study is frequently cited for Noopept, yet PubMed indexes both the English translation and the Russian original without an abstract, so the number of patients, the blinding and the results cannot be checked from the indexed record. Its title describes a comparison of two drugs, and a head-to-head comparison on its own cannot show whether either one beat no treatment.
Laboratory analysis of over-the-counter supplements labeled as containing racetam-type drugs (Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I 2021, Neurol Clin Pract 11(3):e303-e307, PMID 34484905). A product-quality study, not a clinical trial.
Ten cognitive enhancement supplements bought online in the US; no human participants.
Omberacetam was present in all 10 products at 5.1 to 40.6 mg per serving, against a typical pharmacologic dose of 10 mg. Of 12 declared drug quantities, 9 were inaccurate, ranging from 0% to 135% of the label. Two products held undeclared aniracetam, phenibut or picamilon, and one product combined four unapproved drugs.
Market surveillance study by 12 official medicines control laboratories in Europe and Australia (Vanhee C, Deconinck E, George M, et al. 2025, J Xenobiot 15(3):88, PMID 40558871).
159 samples of suspected smart drugs and nootropics collected from January 2020 to September 2024, most sold as dietary supplements or medicines and most from the illegal market.
Noopept was the most commonly detected racetam, often seized as bulk raw material of up to 100% purity, and one liquid held 20 mg/mL, twice the typical oral dose used in Russia. The laboratories note it is not authorised for human use in the EU or Australia and warn that consumers buying such products as supplements may not know they are taking a drug.